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Background 
Polypharmacy is associated with drug–drug interactions, adverse drug events, 
hospitalization, increased mortality and rising costs. Older cancer patients are potentially 
vulnerable to polypharmacy because cancer treatment often involves exposure to 
chemotherapy and other adjunctive or supportive medication. Furthermore, the majority of 
elderly patients with cancer have pre-existing medical conditions requiring 
pharmacotherapy. This study allowed us to characterize the drugs administered to elderly 
patients undergoing chemotherapy treatments and to investigate the prevalence of 
polypharmacy. 
 
Method 
This was an observational and transversal study of older cancer patients admitted to three 
different medical centres of both genders aged > 65 years old undergoing chemotherapy 
treatments. The medication review included patient self-report and medical records. This 
study included 559 elderly patients. Mean age was 71.9 years (SD = 0.2). 44 % were women. 
Mean number of medications reported was 5. The total number of medications used for the 
559 patients was 2699, 58 % of them corresponding to drugs administered out of cancer 
treatment contexts. 
 
Results 
When analysed individually, the most prescribed drugs were Proton Pump Inhibitors 
(261/559; 47 %); HMG CoA reductase inhibitors (161/ 559; 29 %); Anxiolytics, 
Benzodiazepine derivatives (149; 27 %); Drugs for Functional Gastrointestinal Disorders, 
Propulsives (106/559; 19 %) and Analgesics and Antipyretics, Anilides (96/559; 17 %). The 
prevalence of polypharmacy (> = 5 medications) was 48 %. 
 
Conclusions 
Polypharmacy is prevalent in older people with cancer. A careful assessment of the 
medication used in older patients needs to be part of the routine evaluation to minimize risks 
associated with polypharmacy. However, more research is needed to identify strategies to 
simplify patients’ medication regimens. 
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